1.85Open1.85Pre Close0 Volume1 Open Interest17.50Strike Price0.00Turnover123.78%IV1.31%PremiumAug 16, 2024Expiry Date1.60Intrinsic Value100Multiplier24DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.6711Delta0.0584Gamma5.83Leverage Ratio-0.0465Theta0.0065Rho3.91Eff Leverage0.0181Vega
Cullinan Therapeutics Stock Discussion
NEWS
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
• $Cullinan Therapeutics(CGEM.US)$ +22.4% (Cullinan Management and Taiho Pharmaceutical to collaborate to jointly develop and commercialize CLN081/TAS6417 and Taiho's acquisition of Cullinan Pearl)
• $Lordstown Motors(RIDE.US)$ +17.2% (closes asset purchase agreement with Foxconn)
• $Applovin(APP.US)$ +15.5%(In reaction to earnings)
• $SmartRent(SMRT.US)$ +15.4%(In reaction to earnings)
• $Coupang(CPNG.US)$ +14.3%(In reaction to earn...
No comment yet